Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma.
about
Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.Bortezomib for previously untreated multiple myeloma.Efficacy of bortezomib as first-line treatment for patients with multiple myeloma.Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos.
P2860
Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Bortezomib and thalidomide, a ...... atients with multiple myeloma.
@ast
Bortezomib and thalidomide, a ...... atients with multiple myeloma.
@en
type
label
Bortezomib and thalidomide, a ...... atients with multiple myeloma.
@ast
Bortezomib and thalidomide, a ...... atients with multiple myeloma.
@en
prefLabel
Bortezomib and thalidomide, a ...... atients with multiple myeloma.
@ast
Bortezomib and thalidomide, a ...... atients with multiple myeloma.
@en
P2093
P2860
P1476
Bortezomib and thalidomide, a ...... atients with multiple myeloma.
@en
P2093
Anna Ferguson
Carol Ann Huff
Ivan Borrello
Nilanjan Ghosh
P2860
P304
P356
10.1111/J.1365-2141.2010.08534.X
P407
P577
2011-01-17T00:00:00Z